One-year real-world outcomes after vericiguat initiation in heart failure: The ROVER-Japan cohort study
This study provides real-world insights into the contemporary use and outcomes of vericiguat in a large, diverse HF population.
Authors
- Suguru Okami (ORCID: https://orcid.org/0000-0003-4402-0209)
- Christoph Ohlmeier (ORCID: https://orcid.org/0000-0002-2868-5211)
- Makiko Takeichi
- Alexander Michel (ORCID: https://orcid.org/0000-0002-8107-5818)
- Kotaro Nochioka (ORCID: https://orcid.org/0000-0001-8297-8624)
- Yoshifumi Arita (ORCID: https://orcid.org/0009-0000-8869-2758)
- Katsiaryna Holl
- H Yamamoto
- S W Kim
- Shun Kohsaka
Institutions
- IQVIA (United Kingdom) (GB)
- Tohoku University Hospital (JP)
- Keio University Hospital (JP)
- Bayer (Switzerland) (CH)
- IQ Solutions (US)
- Takeda (Japan) (JP)
- Bayer (Germany) (DE)
Publication Details
- Journal
- IJC Heart & Vasculature
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1016/j.ijcha.2026.101900
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00